الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Objective : to assess the neuromuscular and haemodynamic effects of cisatracurium in patients with hepatic cirrhosis. Design : Prospective Randomized study Setting : Mansoura Gastroenterology Centre Method: This study was done on 40 patients aged between (20-50) years. Patients were divided into two groups each group 20 patient. Group A : patients free from liver disease. Group B : patients with evident hepatic cirrhosis. Patients received cisatracurium in a dose of 0.2 mg/ kg. Neuromuscular monitoring was accomplished by TOF to evaluate the neuromuscular blocking effect of cisatracurium. Results: The results of this study revealed that the onset time of action of cisatracurium was significantly slower in cirrhotic group, 10% poor intubating condition at intubation time in the same group. However, the clinical duration of neuromuscular blockade and recovery after multiple increments showed no difference between both groups. There were no recorded significant differences as regard to hemodynamics and side effects. Conclusions : A dose of 0.2 mg/kg of cisatracurium in cirrhotic patients is not at all suitable to produce a clinically accepted intubating condition within 3 minutes. While, maintenance doses and recovery profile do not require dosage adjustment as compared to non cirrhotic patients. Cisatracurium does not cause histamine release resulting in hemodynamic stability in both groups during period of study.